Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT-ON COMPLETION OF THE ISSUANCE OF THE FIRST TRANCHE MEDIUM-TERM NOTES FOR 2022（H SHARES）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT

ON COMPLETION OF THE ISSUANCE OF THE FIRST TRANCHE

MEDIUM-TERM NOTES FOR 2022

Reference is made to the announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the''Company'') dated 23 June 2020 (the ''Announcement'') in relation to the Notice of Acceptance for Registration (Zhong Shi Xie Zhu [2020] No. MTN677) issued by the Association on 18 June 2020 regarding the acceptance of the registration of the medium-term notes. The registered amount of the medium-term notes is RMB5 billion, which is effective for two years commencing from 18 June 2020, and issuable in tranches within the Effective Registration Period. Unless otherwise specified, capitalized terms used herein shall have the same meaning as ascribed to them in the Announcement.

- 1 -

The Company has recently completed the issuance of the first tranche of medium-term notes for 2022 (the ''Current Tranche of Medium-term Notes'') within the above registered amount. The results of the issuance of Current Tranche of Medium-term Notes are set out below:

Name of Current Tranche of	The First Tranche of Medium-term Notes of Shanghai Fosun
Medium-term Notes	Pharmaceutical (Group) Co., Ltd. for 2022* (上海復星醫藥
	(集團)股份有限公司2022年度第一期中期票據)
Short Name of the Current	22 Fosun Pharma	Code of the	102280457
Tranche of Medium-term Notes	MTN001*	Current Tranche
	(22復星醫藥	of Medium-term
	MTN001)	Notes
Aggregate principal amount	RMB0.5 billion	Term of the	Two + two years
		Current Tranche
		of Medium-term
		Notes

Method of interest calculation Fixed interest rate, interest payment once a year, principal and interest repayment once due

Nominal value per unit	RMB100	Coupon rate	3.50%
Value date	9 March 2022	Payment date	9 March 2026
Leading underwriter	China Merchants Bank Co., Ltd.*
Joint leading underwriter	Bank of Ningbo Co., Ltd.*

The relevant documents in relation to the Current Tranche of Medium-term Notes have been published on the website of China Money at http://www.chinamoney.com.cn and the website of Shanghai Clearing House at http://www.shclearing.com.

- 2 -

This announcement does not constitute, or form part of, an offer or invitation, or solicitation or inducement of an offer, to subscribe for or purchase the Current Tranche of Medium-term Notes or any of other securities of the Company, nor is this announcement circulated to invite offers for any securities of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, PRC

9 March 2022

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang, Mr. Wang Kexin and Ms. Guan Xiaohui; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

• For identification purposes only

- 3 -